Get started
BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

BMY chart


Full chart

Key facts today

Bristol-Myers Squibb's acquisition of Celgene for $74 billion in 2019 is highlighted as a significant transaction that has faced challenges due to increased antitrust scrutiny in recent years.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪109.15 T‬ ARS
Dividend yield (indicated)
2.41%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3,481.202 ARS
Net income (FY)
‪6.49 T‬ ARS
Revenue (FY)
‪36.38 T‬ ARS
Shares float
‪2.03 B‬
Beta (1Y)
0.31

About Bristol-Myers Squibb Company


Sector
Health Technology
CEO
Christopher S. Boerner
Headquarters
Princeton
Website
bms.com
Founded
1933
ISIN
ARDEUT112877
FIGI
BBG000L7BMZ1
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BMY news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMY highest yielding bonds


C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.45%
Maturity date
Aug 15, 2043
BMY.GC
Bristol-Myers Squibb Company 6.875% 01-AUG-2097
Yield to maturity
6.02%
Maturity date
Aug 1, 2097
C
BMY4275603
Celgene Corporation 5.0% 15-AUG-2045
Yield to maturity
5.94%
Maturity date
Aug 15, 2045
C
BMY3685700
Celgene Corporation 5.7% 15-OCT-2040
Yield to maturity
5.92%
Maturity date
Oct 15, 2040
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
5.89%
Maturity date
Nov 15, 2047
US110122EC8
BRIST.MYERS 23/63
Yield to maturity
5.69%
Maturity date
Nov 15, 2063
C
BMY4597874
Celgene Corporation 4.55% 20-FEB-2048
Yield to maturity
5.67%
Maturity date
Feb 20, 2048
US110122EL8
BRIST.MYERS 24/64
Yield to maturity
5.60%
Maturity date
Feb 22, 2064
US110122EB0
BRIST.MYERS 23/53
Yield to maturity
5.53%
Maturity date
Nov 15, 2053
US110122EK0
BRIST.MYERS 24/54
Yield to maturity
5.45%
Maturity date
Feb 22, 2054
BMY5007349
Bristol-Myers Squibb Company 5.25% 15-AUG-2043
Yield to maturity
5.43%
Maturity date
Aug 15, 2043

Explore more bonds 

Sparks


Curated watchlists where BMY is featured.

See all sparks